ALTO NEUROSCIENCE INC (ANRO:NYSE)
$20.02 -0.05 (-0.2491%)
Analysed ALTO NEUROSCIENCE INC (ANRO:NYSE) News Sources
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
02-04-2026
yahoo.com
Sector Update: Health Care Stocks Softer Late Afternoon
02-04-2026
yahoo.com
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
02-04-2026
yahoo.com
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
21-04-2026
yahoo.com
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
04-05-2026
yahoo.com
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
11-05-2026
yahoo.com
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
13-05-2026
yahoo.com
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
15-05-2026
yahoo.com
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
27-05-2026
fool.com
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
28-05-2026
yahoo.com
What is the current price of ALTO NEUROSCIENCE INC (ANRO:NYSE)?
The current price of ALTO NEUROSCIENCE INC (ANRO:NYSE) is $20.02.
ALTO NEUROSCIENCE INC (ANRO:NYSE) absolute price change since previous trading day?
The absolute price change of ALTO NEUROSCIENCE INC (ANRO:NYSE) since the previous trading day is $-0.05.
ALTO NEUROSCIENCE INC (ANRO:NYSE) percentage price change since previous trading day?
The percentage price change of ALTO NEUROSCIENCE INC (ANRO:NYSE) since the previous trading day is -0.2491%.
What is the most recent average sentiment score for ALTO NEUROSCIENCE INC (ANRO:NYSE)?
The most recent average sentiment score for ALTO NEUROSCIENCE INC (ANRO:NYSE) is 81 out of 100.
What is the most recent average sentiment for ALTO NEUROSCIENCE INC (ANRO:NYSE)?
The most recent sentiment for ALTO NEUROSCIENCE INC (ANRO:NYSE) is .
SEC-8K** Filing Available For ALTO NEUROSCIENCE INC (ANRO:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.